Available Technologies

Details

Project TitleNovel Immunotherapeutics Using Synthetic Exosomes
Track Code2018-005
Short Description
Abstract
 
Tagsexosome,  immunotherapeutics, nanomedicine, oncology
 
Posted DateSep 18, 2017 1:41 PM

Market Opportunity

A major roadblock for many targeted cancer therapies is reduced effectiveness of the therapeutic due to degradation by the endosomal-lysosomal pathway. Exosomes are a robust vehicle for targeted drug delivery that can directly fuse to the cell membrane and bypass degradation. Their low immunogenicity and nontoxic nature has garnered efforts to adapt them into immunotherapeutics. An improved multifunctional extracellular vesicle with an advanced efficacy and safety profile would disrupt a multibillion-dollar-a-year industry. 

USC Solution

USC researchers have developed first-in-class, dual function exosomes able to recognize both cancer and immune cells to enhance immune response. The spherical orientation of antigen binding arms helps facilitate efficient immune synapse formation between tumor and immune celsl for eliciting greater immune cell response. When used to deliver immune checkpoint inhibitors, these exosomes improve treatment efficacy compared to conventional delivery methods.

Value Proposition

  • Non immunogenic, dual targeting exosomes for targeted drug delivery and immune cell activation 

  • Direct delivery of therapeutics into cells increases therapeutic effect  

  • Spherical geometry facilitates effective immune synapse formation for greater immune response 

  • Amenable to delivery of a wide range of therapeutics to enhance treatment 

Applications

  • A vesicle based therapeutic delivery system for cancer treatment

Stage of Development

  • Validated in vitro. In vivo studies are underway 

  • Available for exclusive or non-exclusive license 

Intellectual Property

Status:

Patent Pending


Key Publication:

“Exosomal-based Therapeutic Drug Delivery Vesicles.” Manuscript in the works.

Contact Information

David Mellman, Licensing Associate

USC Stevens Center for Innovation

(213) 821-3545

dmellman@usc.edu

Files

File Name Description
NCD 2018-005 - Novel Immunotherapeutics Using Synthetic Exosomes.pdf None Download